Inhibition of cancer progression by rifampicin: Involvement of antiangiogenic and anti-tumor effects

Cell Cycle

Volumn 9, Issue 1, 2010, Pages 64-68

  Shichiri, Masayoshi ^a,b   Tanaka, Yujiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Cancer; Endostatin; Endothelium; Rifampicin

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; RIFAMPICIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENTEROHEPATIC CIRCULATION; HUMAN; HUMAN CELL; LIVER TUMOR; LOW DRUG DOSE; MITOGENESIS; REVIEW;

EID: 74549215257     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.1.10354     Document Type: Review

References (34)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-6.
2. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev 2002; 2:727-39.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-60.
4. Folkman J. Tumor angiogenesis. The molecular basis of cancer. Philadelphia: W.B. Saunders 1995; 206-32.
5. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-74.
6. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009;6:395-404.
7. Folkman J. Endogenous angiogenesis inhibitors. Apmis 2004; 112:496-507.
8. Folkman J. Antiangiogenesis in cancer therapyendostatin and its mechanisms of action. Exp Cell Res 2006; 312:594-607.
9. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7.
10. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB Journal 2001; 15:1044-53.
11. Skovseth DK, Veuger MJ, Sorensen DR, et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005; 105:1044-51.
12. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13:649-63.
13. Shichiri M, Fukai N, Kono Y, et al. Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers. Cancer Res 2009; 69:4760-8.
14. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alphavbeta3 for angiogenesis. Science 1994; 264:569-71.
15. Dhanabal M, Ramchandran R, Waterman M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274:11721-6.
16. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999; 96:2811-6.
17. Yamori T, Matsunaga A, Sato S, et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999; 59:4042-9.
18. Yamori T, Sato S, Chikazawa H, et al. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jap J Cancer Res 1997; 88:1205-10.
19. Dan S, Tsunoda T, Kitahara O, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62:1139-47.
20. Fukazawa H, Li PM, Mizuno S, et al. Method for simultaneous detection of protein kinase A, protein kinase C, protein tyrosine kinase, and calmodulindependent protein kinase activities. Anal Biochem 1993; 212:106-10.
21. Murakami Y, Fukazawa H, Mizuno S, et al. Conversion of epidermal growth factor (EGF) into a stimulatory ligand for A431-cell growth by herbimycin A by decreasing the level of expression of EGF receptor. Biochem J 1994; 301:57-62.
22. Li PM, Fukazawa H, Mizuno S, et al. Evaluation of protein kinase inhibitors in an assay system containing multiple protein kinase activities. Anticancer Res 1993; 13:1957-64.
23. Ueda J, Kajita M, Suenaga N, et al. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003; 22:8716-22.
24. Drubin DG, Feinstein SC, Shooter EM, et al. Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J Cell Biol 1985; 101:1799-807.
25. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269:7-17.
26. Kijima M, Yoshida M, Sugita K, et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993; 268:22429-35.
27. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3:108-27.
28. McConnell JB, Powell-Jackson PR, Davis M, et al. Use of liver function tests as predictors of rifampicin metabolism in cirrhosis. Q J Med 1981; 50:77-82.
29. Bachs L, Pares A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1:574-6.
30. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
31. Brem H, Gresser I, Grosfeld J, et al. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 1993; 28:1253-7.
32. Minischetti M, Vacca A, Ribatti D, et al. TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br J Haematol 2000; 109:829-37.
33. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998; 58:5551-8.
34. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36.